Petah Tikva, Israel
Petah Tikva, Israel

Time filter

Source Type

Patent
Can Fite Biopharma Ltd. | Date: 2010-05-06

The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A_(3 )adenosine receptor (A_(3)AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more opthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred A_(3)RAg in accordance with the invention is N^(6)-(3-iodobenzyl)-adenosine-5-N-methyluronamide (IB-MECA).


The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N^(6)-(3-iodobenzyl)-adenin-9-yl]--D-ribofuronamide (IB-MECA) (total daily administration of 4 mg) to subjects having moderate to severe psoriasis, was significantly more effective in treatment of the psoriatic plaques than treatment of psoriasis at two administration doses of 1 mg or 4 mg (total daily doses of 2 or 8 mg, respectively). Thus, the present invention provides a pharmaceutical composition for the treatment of psoriasis comprising as the active ingredient IB-MECA in an amount suitable for a total daily dose administration of about 4 mg. In one preferred embodiment IB-MECA is administered twice a day to a subject in need of psoriasis treatment, the pharmaceutical composition comprising an administration dose of 2 mg.


Patent
Can Fite Biopharma Ltd. | Date: 2013-08-22

Inflammatory state in a subject is assayed by determining the level of expression of A_(3 )adenosine receptor (A_(3)AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A_(3)AR is indicative of an inflammatory state in the subject. This assay can be used for determining whether a patient known to have an inflammatory state should be treated with an A_(3)AR agonist to reduce the inflammatory state. The patient will be so treated only if the level of A_(3)AR in the WBC of the subject is above a predefined threshold, which is about twice the level of A_(3)AR in WBC of healthy subjects. The inflammatory state may particularly be rheumatoid arthritis or uveitis.


Patent
Can Fite Biopharma Ltd. | Date: 2010-06-21

Inflammatory state in a subject is assayed by determining the level of expression of A_(3 )adenosine receptor (A_(3)AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A_(3)AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A_(3)AR agonist.


Patent
Can Fite Biopharma Ltd. | Date: 2013-01-23

The present disclosure concerns the A_(3 )adenosine receptor agonist, 2-Chloro-N^(6)-(3-iodobenzyl)-adenosine-5-N-methyluronamide (Cl-IB-MECA) in an amount of at least about 10 mg/day, for use in treatment of hepatocellular carcinoma (HCC). The present invention also provides Cl-IB-MECA for use in maintenance of liver function in a subject having a chronic liver disease, such as cirrhosis. The liver function is considered as maintained if level of at least one physiological parameter indicative of liver function is essentially constant between two or more time points, i.e. the difference between the two time points does not exceed a medically acceptable tolerance.


Patent
Can Fite Biopharma Ltd. | Date: 2010-05-16

The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A_(3)R agonist.


Patent
Can Fite Biopharma Ltd. | Date: 2013-08-08

The present disclosure provides an A_(3 )adenosine receptor (A_(3)AR) ligand for the treatment of sexual dysfunction. In some embodiments the A_(3)AR ligand is selected from an A_(3)AR agonist and A_(3)AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A_(3 )adenosine receptor (A_(3)AR) ligand. In some embodiments, the A_(3)AR ligand is an A_(3)AR agonist and more specifically, IB-MECA.


Patent
Can Fite Biopharma Ltd. | Date: 2014-08-21

The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A_(3)AR agonist. A preferred A_(3)AR agonist disclosed herein is Cl-IB-MECA.


Patent
Can Fite Biopharma Ltd. | Date: 2016-05-20

Provided is an A_(3 )adenosine receptor agonist (A_(3)AR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method includes administering to said subject in need of said treatment an amount of A_(3)AR agonist, the amount being effective to treat or prevent the development of OA. Preferred but not exclusive A_(3)AR agonists in accordance with the present subject matter are IB-MECA and Cl-IB-MECA. The A_(3)AR agonist may be administered in combination with another drug, such as Methotrexate (MTX). Also provided are pharmaceutical compositions for treatment of osteoarthritis including an amount of an A_(3)AR agonist.


PETACH TIKVA, Israel, Nov. 1, 2016 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory and liver diseases, cancer and sexual dysfunction, today announced...

Loading Can Fite BioPharma Ltd collaborators
Loading Can Fite BioPharma Ltd collaborators